$HLVX
HilleVax, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024525 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.543M $4.577M $3.064M
YoY Change 105.91% 49.38%
% of Gross Profit
Research & Development $17.56M $13.32M $39.29M
YoY Change 109.22% -66.11%
% of Gross Profit
Depreciation & Amortization $1.000K $0.00 $1.000K
YoY Change -50.0% -100.0%
% of Gross Profit
Operating Expenses $23.10M $17.89M $42.35M
YoY Change 108.61% -57.76%
Operating Profit -$17.89M -$39.68M
YoY Change -54.9%
Interest Expense $1.961M $205.0K -$734.0K
YoY Change -192.94% -127.93%
% of Operating Profit
Other Income/Expense, Net -$50.00K $1.087M -$21.99M
YoY Change -99.79% -104.94%
Pretax Income -$21.19M -$16.81M -$65.08M
YoY Change -43.24% -74.18%
Income Tax
% Of Pretax Income
Net Earnings -$21.19M -$16.81M -$65.08M
YoY Change -43.24% -74.18%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$10.03
Diluted Earnings Per Share -$0.56 -$0.45 -$2.055M
COMMON SHARES
Basic Shares Outstanding 33.35M 33.43M 6.167M
Diluted Shares Outstanding 37.32M 6.167M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $279.4M $292.1M $129.6M
YoY Change 124.3% 125.39%
Cash & Equivalents $279.4M $292.1M $129.6M
Short-Term Investments
Other Short-Term Assets $11.21M $8.094M $49.00K
YoY Change 7851.77% 16418.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $290.6M $300.2M $129.6M
YoY Change 133.04% 131.55%
LONG-TERM ASSETS
Property, Plant & Equipment $5.586M $600.0K $207.0K
YoY Change 13200.0% 189.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $22.00K $21.00K $332.0K
YoY Change -99.01% -93.67%
Total Long-Term Assets $26.60M $21.92M $539.0K
YoY Change 984.75% 3967.16%
TOTAL ASSETS
Total Short-Term Assets $290.6M $300.2M $129.6M
Total Long-Term Assets $26.60M $21.92M $539.0K
Total Assets $317.2M $322.1M $130.2M
YoY Change 149.46% 147.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.744M $875.0K $1.225M
YoY Change 363.28% -28.57%
Accrued Expenses $8.210M $7.700M $1.683M
YoY Change -10.41% 357.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $139.5M
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.05M $8.633M $193.5M
YoY Change -94.27% -95.54%
LONG-TERM LIABILITIES
Long-Term Debt $14.79M $4.737M $0.00
YoY Change
Other Long-Term Liabilities $575.0K $379.0K $160.0K
YoY Change 57400.0% 136.88%
Total Long-Term Liabilities $15.37M $5.116M $160.0K
YoY Change 1536600.0% 3097.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.05M $8.633M $193.5M
Total Long-Term Liabilities $15.37M $5.116M $160.0K
Total Liabilities $49.98M $34.88M $193.7M
YoY Change -78.07% -81.99%
SHAREHOLDERS EQUITY
Retained Earnings -$265.0M -$243.8M
YoY Change 151.93%
Common Stock $532.5M $531.0M
YoY Change 11928.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $267.2M $287.2M -$63.50M
YoY Change
Total Liabilities & Shareholders Equity $317.2M $322.1M $130.2M
YoY Change 149.46% 147.43%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$21.19M -$16.81M -$65.08M
YoY Change -43.24% -74.18%
Depreciation, Depletion And Amortization $1.000K $0.00 $1.000K
YoY Change -50.0% -100.0%
Cash From Operating Activities -$18.52M -$19.55M -$2.684M
YoY Change 341.51% 628.28% 179.58%
INVESTING ACTIVITIES
Capital Expenditures $3.829M -$185.0K -$15.00K
YoY Change -12863.33% 1133.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$2.763M
YoY Change -100.0%
Cash From Investing Activities -$3.829M -$185.0K -$2.778M
YoY Change 12663.33% -93.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.687M -2.820M 135.0M
YoY Change -1327.76% -102.09% 13006.89%
NET CHANGE
Cash From Operating Activities -18.52M -19.55M -2.684M
Cash From Investing Activities -3.829M -185.0K -2.778M
Cash From Financing Activities 9.687M -2.820M 135.0M
Net Change In Cash -12.66M -22.55M 129.5M
YoY Change 152.52% -117.41% 184955.71%
FREE CASH FLOW
Cash From Operating Activities -$18.52M -$19.55M -$2.684M
Capital Expenditures $3.829M -$185.0K -$15.00K
Free Cash Flow -$22.35M -$19.36M -$2.669M
YoY Change 436.65% 625.44% 178.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001888012
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41365
dei Entity Registrant Name
EntityRegistrantName
HILLEVAX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0545060
dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100 - #9995
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
213-5054
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
HLVX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33345260
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292060000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124566000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8094000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
141000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
300154000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
124707000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
600000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19670000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2221000
CY2022Q3 us-gaap Assets
Assets
322076000
CY2021Q4 us-gaap Assets
Assets
127159000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
875000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1024000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7699000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9164000
CY2022Q3 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
25000
CY2021Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
2821000
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
158276000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
32000
CY2021Q4 hlvx Warrant Liabilities Related Party
WarrantLiabilitiesRelatedParty
56445000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8633000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227762000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21134000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4737000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
379000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000
CY2022Q3 us-gaap Liabilities
Liabilities
34883000
CY2021Q4 us-gaap Liabilities
Liabilities
227916000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33345260
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9225321
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31563386
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6599886
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
530995000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4426000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243805000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105184000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
287193000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
322076000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127159000
CY2022Q3 us-gaap Related Party Costs
RelatedPartyCosts
719000
CY2021Q3 us-gaap Related Party Costs
RelatedPartyCosts
0
us-gaap Related Party Costs
RelatedPartyCosts
2313000
us-gaap Related Party Costs
RelatedPartyCosts
15000
CY2022Q3 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
13315000
CY2021Q3 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
896000
hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
28352000
hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
1623000
CY2021Q3 hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
37666000
hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
2500000
hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
37666000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
37000
CY2021Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
215000
CY2022Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
3000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
599000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4577000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1113000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11162000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3064000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
17892000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
39675000
us-gaap Operating Expenses
OperatingExpenses
42014000
us-gaap Operating Expenses
OperatingExpenses
42353000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17892000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-39675000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42014000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42353000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1317000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1657000
CY2022Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2021Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
182000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
717000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
199000
CY2022Q3 us-gaap Interest Expense
InterestExpense
205000
CY2021Q3 us-gaap Interest Expense
InterestExpense
717000
us-gaap Interest Expense
InterestExpense
3157000
us-gaap Interest Expense
InterestExpense
734000
CY2022Q3 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
0
CY2021Q3 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
918000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
13196000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
1435000
CY2021Q3 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
875000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
51469000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
1392000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
20598000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
43575000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
20598000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1087000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22193000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-96607000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22728000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16805000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-61868000
us-gaap Net Income Loss
NetIncomeLoss
-138621000
us-gaap Net Income Loss
NetIncomeLoss
-65081000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.03
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.26
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37323626
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37323626
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6166500
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6166500
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23640388
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23640388
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5306710
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5306710
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
303154000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
844000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16805000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
287193000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-5986000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000
CY2021Q3 hlvx Stock Issued During Period Value Vesting Of Restricted Shares
StockIssuedDuringPeriodValueVestingOfRestrictedShares
1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-61868000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-63497000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
hlvx Stock Issued During Period Value Conversion Of Notes And Accrued Interest Into Common Shares
StockIssuedDuringPeriodValueConversionOfNotesAndAccruedInterestIntoCommonShares
215364000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
100020000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1672000
us-gaap Net Income Loss
NetIncomeLoss
-138621000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
287193000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2773000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000
hlvx Vesting Restrictions Placed On Previously Issued And Outstanding Common Stock
VestingRestrictionsPlacedOnPreviouslyIssuedAndOutstandingCommonStock
1000
us-gaap Net Income Loss
NetIncomeLoss
-65081000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-63497000
us-gaap Profit Loss
ProfitLoss
-138621000
us-gaap Profit Loss
ProfitLoss
-65081000
us-gaap Depreciation
Depreciation
1000
us-gaap Share Based Compensation
ShareBasedCompensation
1672000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
13196000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
1435000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
51469000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
1392000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
43575000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
20598000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
182000
us-gaap Paid In Kind Interest
PaidInKindInterest
48000
hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
2500000
hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
37666000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-42000
hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
0
hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
47000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7951000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24000
hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-4137000
hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-89000
hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
-713000
hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
1616000
hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
717000
hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
205000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2823000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
734000
hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
1502000
hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-3000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43472000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3101000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2500000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2763000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
185000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2685000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2778000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230006000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
19389000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
4665000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
135000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215282000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135001000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
169125000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
129122000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
124566000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
457000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
293691000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129579000
us-gaap Interest Paid Net
InterestPaidNet
104000
hlvx Accrued Interest Exchanged For Convertible Promissory Notes
AccruedInterestExchangedForConvertiblePromissoryNotes
47000
hlvx Noncash Or Part Noncash Operating Lease
NoncashOrPartNoncashOperatingLease
20317000
hlvx Noncash Or Part Noncash Operating Lease
NoncashOrPartNoncashOperatingLease
180000
hlvx Warrants Issued
WarrantsIssued
30534000
us-gaap Stock Issued1
StockIssued1
4357000
hlvx Unpaid Initial Public Offering Costs
UnpaidInitialPublicOfferingCosts
313000
hlvx Unpaid Initial Public Offering Costs
UnpaidInitialPublicOfferingCosts
309000
hlvx Unpaid Property And Equipment Purchases
UnpaidPropertyAndEquipmentPurchases
415000
hlvx Conversion Of Convertible Promissory Notes And Interest Into Common Stock
ConversionOfConvertiblePromissoryNotesAndInterestIntoCommonStock
215364000
hlvx Conversion Of Warrant Liability Into Equity
ConversionOfWarrantLiabilityIntoEquity
100020000
hlvx Accreted Final Interest Payment Fees
AccretedFinalInterestPaymentFees
158000
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.681
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5883500
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0000595
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292060000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
293691000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7700000
CY2022Q3 hlvx Accrued Research And Development
AccruedResearchAndDevelopment
3500000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2800000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1400000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
1954126
CY2021Q3 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
3049685
hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2214463
hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2699099
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3585049
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2734764
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y2M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
30000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3480000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3581000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3685000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3782000
CY2022Q3 hlvx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
24935000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39493000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12336000
CY2022Q3 hlvx Lessee Operating Lease Tenant Improvement Reimbursements
LesseeOperatingLeaseTenantImprovementReimbursements
5989000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
21168000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21134000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2022Q3 hlvx Accumulated Paid In Kind Interest Amount
AccumulatedPaidInKindInterestAmount
48000
CY2022Q3 hlvx Debt Instrument Carrying Amount Including Paid In Kind Interest
DebtInstrumentCarryingAmountIncludingPaidInKindInterest
5048000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
311000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
4737000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
77000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
316000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
327000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1690000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2661000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3980000
CY2022Q3 hlvx Principal Payments Interest Payments And Final Payment Fee
PrincipalPaymentsInterestPaymentsAndFinalPaymentFee
9051000
CY2022Q3 hlvx Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
4003000
CY2022Q3 hlvx Long Term Debt Net Of Interest Pik Interest And Back End Fee
LongTermDebtNetOfInterestPikInterestAndBackEndFee
5048000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4547570
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.027
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.040
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.040
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.929
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.943
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.834
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.943
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
844000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1672000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M23D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2625435
hlvx Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Number Of Shares Repurchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedNumberOfSharesRepurchased
81949
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
761612
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1781874
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12637059

Files In Submission

Name View Source Status
0000950170-22-024525-index-headers.html Edgar Link pending
0000950170-22-024525-index.html Edgar Link pending
0000950170-22-024525.txt Edgar Link pending
0000950170-22-024525-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hlvx-20220930.htm Edgar Link pending
hlvx-20220930.xsd Edgar Link pending
hlvx-ex31_1.htm Edgar Link pending
hlvx-ex31_2.htm Edgar Link pending
hlvx-ex32_1.htm Edgar Link pending
hlvx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
hlvx-20220930_def.xml Edgar Link unprocessable
hlvx-20220930_lab.xml Edgar Link unprocessable
hlvx-20220930_pre.xml Edgar Link unprocessable
hlvx-20220930_cal.xml Edgar Link unprocessable
hlvx-20220930_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable